Pineridge Advisors LLC Acquires Shares of 1,229 Johnson & Johnson (NYSE:JNJ)

Pineridge Advisors LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,229 shares of the company’s stock, valued at approximately $193,000.

Other large investors also recently bought and sold shares of the company. Keener Financial Planning LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth approximately $40,000. WFA Asset Management Corp lifted its stake in Johnson & Johnson by 61.4% in the fourth quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 97 shares during the last quarter. Vermillion & White Wealth Management Group LLC bought a new stake in Johnson & Johnson in the fourth quarter valued at $44,000. Disciplined Equity Management Inc. bought a new stake in Johnson & Johnson in the fourth quarter valued at $45,000. Finally, Altshuler Shaham Ltd lifted its stake in Johnson & Johnson by 37.8% in the third quarter. Altshuler Shaham Ltd now owns 317 shares of the company’s stock valued at $49,000 after buying an additional 87 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent analyst reports. Bank of America cut their price objective on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. StockNews.com cut shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 10th. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 price target on shares of Johnson & Johnson in a research report on Tuesday, June 4th. HSBC upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and boosted their price target for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. Finally, The Goldman Sachs Group initiated coverage on shares of Johnson & Johnson in a research report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price target on the stock. Eight equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Hold” and a consensus price target of $174.07.

Johnson & Johnson Stock Up 0.1 %

Shares of NYSE:JNJ traded up $0.09 during mid-day trading on Friday, reaching $145.54. 4,075,342 shares of the stock were exchanged, compared to its average volume of 7,121,075. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36. The company has a market cap of $350.27 billion, a P/E ratio of 9.07, a P/E/G ratio of 2.42 and a beta of 0.53. Johnson & Johnson has a one year low of $143.13 and a one year high of $175.97. The stock’s 50 day simple moving average is $148.38 and its 200-day simple moving average is $154.69.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $0.07. The firm had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The business’s revenue was up 2.3% compared to the same quarter last year. During the same period last year, the company earned $2.68 earnings per share. As a group, equities research analysts predict that Johnson & Johnson will post 10.63 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st were given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.41%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend was Monday, May 20th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.